Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05359_nanopub.RAK-ZvEsKF0D7yhhfiFniEmHh38hRAgiHgTiEuaSkNiKM#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05359 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05359 label "VEC-162 [drugbank:DB05359]" assertion.
- drugbank:DB05359 seeAlso DB05359 assertion.
- drugbank:DB05359 identifier "drugbank:DB05359" assertion.
- drugbank:DB05359 description "VEC-162 is a melatonin agonist under development for the treatment of sleep disorders (insomnia, circadian rhythm sleep disorders) and mood disorders (including depression). Vanda licensed VEC-162 from Bristol-Myers Squibb Company in 2004. Vanda has completed phase II for VEC-162 in insomnia and has initiated a phase III trial." assertion.
- drugbank:DB05359 title "VEC-162" assertion.
- drugbank:DB05359 bio2rdf_vocabulary:identifier "DB05359" assertion.
- drugbank:DB05359 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05359 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05359" assertion.
- drugbank:DB05359 bio2rdf_vocabulary:x-identifiers.org DB05359 assertion.
- drugbank:DB05359 drugbank_vocabulary:drugbank-id "DB05359" assertion.
- drugbank:DB05359 drugbank_vocabulary:x-cas cas: assertion.